New Database for Sharing MS Clinical Trial Data
News Apr 26, 2016
This is just one of the tools generated through the Multiple Sclerosis Outcome Assessments Consortium (MSOAC), a global effort launched by the National MS Society and Critical Path Institute (C-Path). MSOAC is striving to develop an outcomes measure that addresses the critical need for a more sensitive way to detect the benefit of potential treatments that slow or reverse progressive disability in people with MS.
“Key to the success of every C-Path consortium is the sharing of expertise and data,” stated Lynn Hudson, PhD, C-Path’s Chief Science Officer and Executive Director of MSOAC. “The sharing of both treatment and placebo arm data by MSOAC member companies is unparalleled.”
Nearly 15,000 records from active treatment and inactive placebo arms, a rich source of performance measures and related clinical information, are currently being analyzed for regulatory qualification of a new instrument to measure disability and progression in MS. The measurement tool, which will also incorporate the viewpoint of people living with MS, will be submitted to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for regulatory qualification, a step toward validating its acceptance for use as a primary outcome measure in clinical trials.
“We’re pleased to enable investigators around the world to access previously unavailable data through the new placebo data platform, which should increase our understanding of MS,” notes Bruce Bebo, PhD, Executive Vice President, Research, at the National MS Society. “MSOAC is the latest in a long line of special initiatives undertaken by the Society to enhance the conduct of MS clinical trials and thereby speed the development of new therapies for all forms of MS. By bringing multiple stakeholders to the table, including people with MS, we have been able to achieve broad support for our goal of better and faster trials.”
Prior to pooling data, standardization is essential. The consortium began by developing another tool—a data standard for MS—in collaboration with the leading global standards organization the Clinical Data Interchange Standards Consortium (CDISC). Released in 2014, this therapeutic area standard allows data from multiple MS trials to be grouped for reporting, analysis, and regulatory submissions. As another advantage for the MS community, the MS data standard will help drug sponsors meet next year’s FDA requirement for implementation of CDISC data standards in individual submissions.
The MS data is housed at C-Path’s Data Collaboration Center (DCC), which was founded to provide large-scale data solutions for scientific research in a neutral, non-competitive environment. Currently, DCC’s data platform securely hosts data from 83 clinical trials, representing over 49,000 subjects, over 100 million data points, and six different therapeutic areas. The DCC’s policies around individual patient-level data meet or exceed data privacy and human subject research protection requirements.
A review board will screen requests for access to the MS placebo arm database, using the process established for another successful C-Path effort in sharing placebo data, namely, the Alzheimer’s disease database. Investigators may apply by supplying a brief description of the research plan and agreeing to the terms and conditions; details and forms are available on the MSOAC website.
Neural Computer Hears Like HumansNews
Modelling the human senses is an incredibly complex task. Our brains arrange cells into complex hierarchies that process information from our surroundings. Now, a group at MIT have created a model of the human auditory cortex that can hear sounds and music in the same way that humans do.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
Deceased Data: Should Your Online Remains Be Treated Like Physical Remains?News
In 2018, your death doesn't just leave behind a body. It leaves behind a huge online footprint - your digital remains. A new study asks whether these remains should be treated and respected as a corpse would, and whether museums may provide a blueprint for the preservation process.READ MORE